louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05275114: Improvement Effect of Transcranial Direct Current Stimulation (tDCS) Applied During Exercise Training in Stroke Patients With Upper Limb and Hand Motor Function
Official title: Improvement Effect of Transcranial Direct Current Stimulation (tDCS) Applied During Exercise Training in Stroke Patients With Upper Limb and Hand Motor Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
Collaborators: name: Cybermedic Co., Ltd.
First posted: 2022-03-11
Enrollment: 24
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to improve the effect of Transcranial Direct Current Stimulation (tDCS) applied during exercise training in stroke patients with upper limb and hand motor function.


Eligibility criteria: Inclusion Criteria:

* Patients aged 19 to 80 years
* Less than 58 FMA Upper scores
* Patients whose lesions do not include stimulation regions
* Patients with stroke with more than 3 months of onset

Exclusion Criteria:

* Difficult to communicate due to severe language impairment.
* Accompanied by an existing serious neurogenic disease
* Existing significant psychiatric disorders such as major schizophrenia, bipolar disorder
* If there are difficulties in conducting the research
* Any patients who are judged by the investigator to be difficult to participate in this study
* Patients with contraindicated MRI scans

Primary outcomes:
measure: Change in Fugl-Meyer Assessment
timeFrame: Session 0 (initial visit);; Session 10 (at approximatel 4 weeks)
Secondary outcomes:
measure: Change in 9-hole pegboard test
timeFrame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
measure: Change in Grip & Tip pinch strength
timeFrame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
measure: Change in Sequential finger tapping reaction time and accruacy
timeFrame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
measure: Change in Jebsen-Taylor hand function test
timeFrame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
measure: Change in Box and Block test
timeFrame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
measure: Changes in motor evoked potential
timeFrame: [Time Frame: session 0 (initial visit); session 10 (at approximately 4 weeks)]
measure: Changes in Brain activation of resting-state functional MRI
timeFrame: [Time Frame: session 0 (initial visit); session 10 (at approximately 4 weeks)]
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
Clinical trial NCT00774514: The Cardiovascular Effects of Nitrogen Dioxide Exposure
Official title: The Cardiovascular Effects of Nitrogen Dioxide Exposure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endothelial Dysfunction
Keywords: Air Pollution
Nitrogen Dioxide
NO2
Endothelial dysfunction
Lead sponsor: University of Edinburgh
Sponsor class: OTHER
Collaborators: name: Umeå University
First posted: 2008-10-17
Enrollment: 12
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Exposure to air pollution has been linked to increased cardiorespiratory morbidity and mortality. The exact component of air pollution that mediates this effect is unknown, but the link is strongest for fine combustion derived particulate matter derived from traffic sources. It has been demonstrated that inhalation of diesel exhaust impairs vascular vasomotor tone and endogenous fibrinolysis. Recent studies using an inline retrofit particle trap to reduce the particulate component of exhaust have shown that filtering particles leads to a reversal of the endothelial dysfunction seen after diesel exhaust exposure, and have even suggested an augmentation of vascular function. This raises the question of the cardiovascular effects of the gaseous pollutants, the most abundant of which is nitrogen dioxide. In this study we plan to investigate the cardiovascular effects of nitrogen dioxide exposure.


Eligibility criteria: Inclusion Criteria:

* Healthy male volunteers

Exclusion Criteria:

* Current smokers
* Significant occupational exposure to air pollution
* Regular medication use
* Intercurrent illness

Primary outcomes:
measure: Forearm blood flow measured by venous occlusion plethysmography in response to intraarterial vasodilators (acetylcholine, sodium nitroprusside, bradykinin and verapamil)
timeFrame: 4-6 hours after exposure
Secondary outcomes:
measure: Plasma t-PA concentrations after infusion of bradykinin
timeFrame: During forearm study
measure: Exhaled nitric oxide
timeFrame: 4-6 hours after exposure
Other outcomes:
Locations:
city: Umeå
country: Sweden
facility: Umeå University
Study officials:
affiliation: Umeå University
name: Thomas Sandström, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Umeå University
name: Anders Blomberg, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02409914: Brain Metabolism in Polycystic Ovary Syndrome
Official title: Brain Metabolism in Women With Polycystic Ovary Syndrome: a PET/MRI Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Insulin Resistance
Keywords: Insulin Resistance
Brain metabolism
PET
MRI
Lead sponsor: Université de Sherbrooke
Sponsor class: OTHER
First posted: 2015-04-07
Enrollment: 7
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with PCOS (n=7) were referred by physician specialist in endocrinology between March, 2010 and September, 2013. The diagnosis of PCOS was based on clinical examination using the Rotterdam criteria.

Brief summary: The purpose of this study is to investigate whether higher insulin resistance in young women with Polycystic ovary syndrome (PCOS) is associated with reduced cerebral metabolic rate of glucose (CMRglu). Brain volumes using magnetic resonance imaging (MRI) and quantitative cerebral glucose uptake using dynamic positron emission tomography (PET) were obtained.

Detailed description: MRI and FDG PET scan for each participant were obtained within an average time frame of 3 weeks. Isulin resistance were assessed with the updated homeostasis model assessment (HOMA2-IR).

Eligibility criteria: Inclusion Criteria:

* Diagnosis of PCOS
* Age ≤ 35 y
* BMI ≤ 35

Exclusion Criteria:

* Taking medications for diabetes or insulin-sensitizing drugs
* Drug addictions
* Psychiatric illness
* Smoking
* Overt evidence of heart, liver or renal disease

Primary outcomes:
measure: Global Brain Glucose PET Uptake
timeFrame: Single point in time (day 1)
measure: Brain MR Volumes
timeFrame: Single point in time (day 2)
measure: Insulin Resistance (HOMA2-IR)
timeFrame: Single point in time (day 1 during the FDG PET)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01312714: Vitamin D3 Supplementation in Dialysis Patients
Official title: A Randomized, Placebo-Controlled, Double Blind Study Evaluating the Effect of Cholecalciferol on Vasoactive Hormones, Heart Function, Arterial Stiffness, and Blood Pressure in Dialysis Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: End-Stage Renal Disease
Keywords: Hemodialysis
Peritoneal dialysis
Vitamin D Deficiency
blood pressure
arterial stiffness
Heart function
Renin-angiotensin system
Calcium
FGF-23
Brain natriuretic peptide
Lead sponsor: Regional Hospital Holstebro
Sponsor class: OTHER
First posted: 2011-03-11
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide. This study will evaluate the effect of 26 weeks of vitamin D3 supplementation in patients with end stage renal disease.


Eligibility criteria: Inclusion Criteria:

* Hemodialysis or peritoneal dialysis \> 3 months

Exclusion Criteria:

* Hypercalceamia
* Cancer
* Inability to give informed consent

Primary outcomes:
measure: Plasma concentration of NT-proBNP
timeFrame: 26 weeks
Secondary outcomes:
measure: Plasma concentration of ionized calcium
timeFrame: 4 weeks
measure: Plasma concentration of phosphate
timeFrame: 4 weeks
measure: Plasma concentration of PTH
timeFrame: 4 weeks
measure: Plasma concentration of 25-hydroxycholecalciferol
timeFrame: 4 weeks
measure: 24-hour blood pressure
timeFrame: 26 weeks
measure: Plasma renin concentration
timeFrame: 26 weeks
measure: Plasma concentration of angiotensin II
timeFrame: 26 weeks
measure: Plasma concentration of aldosterone
timeFrame: 26 weeks
measure: Arterial stiffness
timeFrame: 26 weeks
measure: Serum concentration of FGF-23
timeFrame: 26 weeks
measure: Plasma concentration of AVP
timeFrame: 26 weeks
measure: Plasma concentration of ANP
timeFrame: 26 weeks
measure: Plasma concentration of TNF alpha
timeFrame: 26 weeks
measure: Heart Function
timeFrame: 26 weeks
Other outcomes:
Locations:
city: Holstebro
country: Denmark
facility: Departments of Medical Research and Medicine, Holstebro Hospital
Study officials:
affiliation: Departments of Medical Research and Medicine
name: Erling B Pedersen, M.D., M.Sci.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mose FH, Vase H, Larsen T, Kancir AS, Kosierkiewic R, Jonczy B, Hansen AB, Oczachowska-Kulik AE, Thomsen IM, Bech JN, Pedersen EB. Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial. BMC Nephrol. 2014 Mar 24;15:50. doi: 10.1186/1471-2369-15-50.
Clinical trial NCT03180814: Effects of Whole Body Vibration on Autonomic Function in Healthy Young and Elderly
Official title: Acute Effects of Whole Body Vibration on Autonomic Function in Healthy Young and Elderly
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Aging
Lead sponsor: Universidade Federal de Pernambuco
Sponsor class: OTHER
First posted: 2017-06-08
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aging causes anatomical and physiological changes in the cardiovascular system and autonomic function with decline in its maximum function. This study aimed to evaluate the acute effects of whole body vibration on cardiovascular system, autonomic function and heart variability in healthy young and elderly. The investigators' hypothesis is that whole body vibration has different effects in young and elderly.


Eligibility criteria: Inclusion Criteria:

* Elderly individuals aged between 60 and 80 years
* Young individuals aged between 18 and 30 years
* Able to walk without assistance
* Good understanding to perform the proposed procedures
* Sedentary or low active

Exclusion Criteria:

* Body Mass Index (BMI) \> 35Kg/m2
* Systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg (at rest)
* Difficulty adapting to the whole body vibration
* Smoking
* Neuromuscular or degenerative disorders
* Neurological diseases
* Cardiopulmonary comorbidities
* Cardiac arrhythmias
* Osteoarticular disorders
* Use of hormone replacement therapy
* Use medications or supplements known to affect cardiovascular parameters
* Labyrinthitis

Primary outcomes:
measure: Autonomic Function
timeFrame: Change from Baseline Heart rate variability at 5, 10, 15, 20 and 35 minutes
Secondary outcomes:
measure: Sympathetic modulation
timeFrame: Change from Baseline Sympathetic modulation at 5, 10, 15, 20 and 35 minutes
measure: Parasympathetic modulation
timeFrame: Change from Baseline Parasympathetic modulation at 5, 10, 15, 20 and 35 minutes
measure: Sympathovagal Balance
timeFrame: Change from Baseline Sympathovagal balance at 5, 10, 15, 20 and 35 minutes
measure: Heart Rate
timeFrame: Change from Baseline Heart Rate at 5, 10, 15, 20 and 35 minutes
measure: Blood pressure
timeFrame: Change from Baseline Blood pressure at 5, 10, 15, 20 and 35 minutes
measure: Peripheral oxygen saturation
timeFrame: Change from Baseline Peripheral oxygen saturation at 5, 10, 15, 20 and 35 minutes
measure: Adverse effects
timeFrame: Change from Baseline at 20 minutes
Other outcomes:
Locations:
city: Recife
country: Brazil
facility: Federal University of Pernambuco
state: Pernambuco
Study officials:
References:
Clinical trial NCT03308214: The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients
Official title: The Analysis of Factors Influencing the Apparent Volume of Distribution of Imipenem in Septic Shock Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Septic Shock
Keywords: septic shock; imipenem; VD ;pharmacokinetics
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2017-10-12
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: septic shock patients and non-septic shock patients with the therapy of imipenem in the ICU of Zhongda hospital

Brief summary: The study measures the plasma concentrations of imipenem in septic shock patients and non-septic shock patients and observes hypoalbuminemia and the impact of the severity of critical illness on Vd

Detailed description: Severe sepsis and septic shock are major causes of mortality in intensive care unit(ICU) patients.Correct and adequate antibiotic coverage is essential but can be complex as a result of fluid resuscitation, hypoalbuminemia, organ dysfunction, the application of extracorporeal support modalities and the impact of critical illness on pharmacokinetics(PK).Such changes will significantly distort the normal anti-biotic PK profile, resulting in drug exposure that is markedly different from the 'healthy volunteer.'The apparent volume of distribution is one of important PK parameters.Vd determines the loading dose. This review article considers these issues in detail, summarizing the key changes in antibiotic Vd in the critically ill, and providing general suggestions how to optimization of antibiotic dosing to manage Vd challenges.50 patients who receives the theapy of imipenem are included in this study.Whether hypoalbuminemia, organ dysfunction, the application of extracorporeal support modalities and the impact of critical illness on Vd will be evaluted.

Eligibility criteria: Inclusion Criteria:

1. age between 18 years old and 80 years old;
2. Admitted to the ICU;
3. Patients diagnosed as septic shock requiring the therapy of imipenem(0.5g q6h or 1.0g q8h;

Exclusion Criteria:

1. Patient participated in another interventional trial before enrollment
2. Allergy, hypersensitivity or a serious reaction to imipenem;
3. Pregnancy.
4. patients with ECMO and(or)CRRT.
5. tumors.

Primary outcomes:
measure: the apparent volume of distribution
timeFrame: Day1, Day 3, Day 7
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Zhongda Hospital, Southeast University
state: Jiangsu
Study officials:
affiliation: Study Investigator
name: Songqiao Liu, PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Huang Y, Yang J, Xie J, Liu L, Liu S, Guo F, Qiu H, Yang Y. Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem: A Prospective Cohort Study. J Infect Dis. 2020 Mar 16;221(Suppl 2):S272-S278. doi: 10.1093/infdis/jiz651.
Clinical trial NCT00008814: Functional Magnetic Resonance Imaging in Infants
Official title: Functional Magnetic Resonance Imaging (fMRI) in Infants
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthy
Infant, Newborn, Diseases
Keywords: Cognition
Infant Development
MRI, Functional
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
First posted: 2001-01-18
Sex: ALL
Minimum age (years): 1
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: NATURAL_HISTORY
Time perspective: OTHER

Brief summary: The study proposes to evaluate cognitive development in infants four months or younger by functional MRI and event related potential recording. fMRI imaging will be obtained following an auditory stimulus inside the 4 tesla magnet at the Center for Magnetic Resonance Research and will be correlated with ERP response to the same stimulus.


Eligibility criteria: Male or female infants less than 4 months old

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: St. Paul
country: United States
facility: University of Minnesota, Institute of Child Development
state: Minnesota
Study officials:
References:
Clinical trial NCT01011114: Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
Official title: Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Hypophosphatemia
Renal Transplant
Keywords: hypophosphatemia
hyperparathyroidism
renal transplant
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
First posted: 2009-11-11
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine whether cinacalcet, used in patients with secondary hyperparathyroidism to control excessive parathyroid hormone, can normalize low blood phosphorus that is commonly seen in patients who have had a kidney transplant.

Detailed description: Secondary hyperparathyroidism (SHPT), common in ESRD, persists following renal transplantation resulting in profound hypophosphatemia. This can lead to hemolysis, congestive heart failure, rhabdomyolysis. Phosphate repletion is difficult in view of the persistent SHPT: oral phosphate supplementation can lead to hypocalcemia, reduced 1,25-OH Vitamin D production, hypercalcemia and further hyperparathyroidism. In addition, phospho-soda has been associated with phosphate nephropathy and renal failure.

Cinacalcet HCl is a calcimimetic agent that has recently become a standard therapy in the treatment of SHPT in ESRD. It suppresses PTH secretion by acting as a modulator of the Calcium-sensing receptor on the PTH cell, causing the PTH cell to decrease production of parathyroid hormone. It is a very effective agent, producing significant reduction of PTH as well as improvement in calcium and phosphate metabolism in the dialysis patient. The drug is well-tolerated with minimal adverse effects. Cinacalcet has also been used to control hypercalcemia in renal transplant patients with persistent hyperparathyroidism. Short-term cinacalcet given for 2 to 4 weeks has normalized serum phosphorus and decreased urinary phosphate wasting in renal transplant recipients with stable graft function.

We hypothesize that Cinacalcet HCl will normalize the hypophosphatemia of early renal transplant by reducing the effects of PTH on the proximal renal tubular transport of phosphorus, thereby allowing phosphate reabsorption and decreasing urinary phosphate wasting.

Eligibility criteria: Inclusion Criteria:

* renal transplant within last 3 months
* serum phosphorus less than 2.0 mg/dl
* serum creatinine less than 2.0 mg/dl

Exclusion Criteria:

* sensitivity to cinacalcet
* use of amitryptiline, desipramine, itraconazole, ketoconazole
* pregnancy

Primary outcomes:
measure: improvement in serum phosphorus
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
Study officials:
affiliation: Montefiore Medical Center
name: Maria Coco, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00643214: Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis
Official title: A Study to Determine if Tetrix Cream Impedes the Resolution of Experimentally Induced Allergic Contact Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Tetrix Cream
Antigen reaction
effect on healing
To determine if application of Tetrix Cream to lesions of contact dermatitis interferes with their rate of healing
Lead sponsor: Coria Laboratories, Ltd.
Sponsor class: INDUSTRY
First posted: 2008-03-26
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To determine if Tetrix Cream,, when applied to the skin lesions on patients with contact dermatitis, slows or interferes with the healing of the lesions.


Eligibility criteria: Inclusion Criteria:

* Normal subjects with sensitivity to nickel.

Exclusion Criteria:

* Under 18 years of age.

Primary outcomes:
measure: Clearing of signs and symptoms of contact dermatitis
timeFrame: 10 days after induction of lesion and start of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Louisville
country: United States
facility: Dermatology Specialists, LLC
state: Kentucky
Study officials:
affiliation: Dermatology Specialists, LLC
name: Joseph Fowler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02430714: Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Official title: Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thyroid Neoplasms
Keywords: Thyroid Cancer
Lenvima
Post-marketing surveillance
LEN01T
All-Patient Investigation
Lenvatinib Mesylate
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2015-04-30
Enrollment: 629
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All participants with unresectable thyroid cancer and administrated Lenvatinib in Japan

Brief summary: This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.


Eligibility criteria: Inclusion Criteria:

1. All participants with unresectable thyroid cancer and administrated Lenvatinib.

Primary outcomes:
measure: Number of participants with adverse events (AEs)/adverse drug reactions (ADRs)
timeFrame: up to 1 year
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: up to 1 year
Other outcomes:
Locations:
city: Osaka
country: Japan
city: Tokyo
country: Japan
Study officials:
affiliation: Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd.
name: Yasunori Megumi
role: STUDY_DIRECTOR
References: